Results 171 to 180 of about 7,432 (208)

Comparative Approaches in Treating Double-J Stent Syndrome: Monotherapy or Combination Therapy? [PDF]

J Clin Med
Pricop C, Bandac CA, Ivanuță M, Rădăvoi D, Jinga V, Puia D.   +5 more
europepmc   +1 more source

Significant Nevi Regression Associated with Multiple Non-Metastatic Cutaneous Melanomas: A Case Report. [PDF]

Dermatol Pract Concept
Mokos M, Šitum M, Tomas D, Rogan SA, Buljan M.   +4 more
europepmc   +1 more source

Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health. [PDF]

Curr Urol Rep
Singh D, Nguyen T, Burnam P, Greenberg J, Raheem O, Hellstrom W.   +5 more
europepmc   +1 more source

Tamsulosin: Ureteral Stones [PDF]

Hospital Pharmacy, 2005
Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses.
Joyce A. Generali, Dennis J. Cada
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tamsulosin: an overview

World Journal of Urology, 2002
This article reviews the contemporary literature related to tamsulosin, which is now the most widely used alpha antagonist in treating benign prostatic hyperplasia. The primary emphasis of this article is on the clinical data that exist related to this agent.
Karl-Erik Andersson, Christopher R. Chapple   +1 more
openaire   +3 more sources

Voltammetric investigation of Tamsulosin

Talanta, 2003
The electrooxidative behavior and determination of Tamsulosin HCl (TAM), one of the alpha(1)-adrenoceptor antagonist, on a glassy carbon disc electrode were investigated for the first time by using cyclic, linear sweep, differential pulse (DPV) and square wave voltammetry (SWV). TAM showed an irreversible oxidation behavior at all pH values and buffers
Bengi Uslu, Hassan Y. Aboul-Enein, Sibel A. Ozkan   +2 more
openaire   +3 more sources

Tamsulosin for benign prostatic hyperplasia

Cochrane Database of Systematic Reviews, 2002
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms.This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH ...
Indy Rutks, Roderick MacDonald, Timothy J Wilt   +2 more
openaire   +3 more sources

Metabolism of tamsulosin in rat and dog

Xenobiotica, 1996
1. The metabolism of tamsulosin hydrochloride (TMS), a potent alpha 1-adrenoceptor blocking agent, was studied after a single oral administration to rat and dog. 2. Eleven metabolites (1, 2, 3, 4 and their glucuronides, sulphates of 1 and 3, and A-1) were identified from the urine and bile of rat and dog administered TMS. 3.
H. Matsushima, S. Higuchi, Takashi Watanabe, H. Kaniwa, Y. Teraya, Y. Soeishi   +5 more
openaire   +3 more sources

Tamsulosin for voiding dysfunction in women

International Urology and Nephrology, 2012
Lower urinary tract symptoms (LUTS) affect countless individuals worldwide with an increased prevalence among those≥60 years of age. As the world's population ages, the prevalence of LUTS will continue to increase, diminishing the quality of life of many men and women. For men, alpha-1-adrenergic receptor (α1-AR) blockers are used as first-line therapy
Laura E. Meyer, Jamie N. Brown
openaire   +3 more sources